$TVTX
Travere Therapeutics Inc Stock $tvtx

$tvtx Overview Financials Valuation SEC Filings Company Website

2020 Q2 Form 10-Q Financial Statement

#000143853320000022 Filed on July 31, 2020

Income Statement

Concept	2020 Q2	2019 Q2	2019 Q1
Revenue	$48.43M	$44.71M	$39.57M
YoY Change	8.33%	8.15%	2.96%
Cost Of Revenue	$1.494M	$979.0K	$1.017M
YoY Change	52.6%	-16.89%	-36.95%
Gross Profit	$46.94M	$43.73M	$38.55M
YoY Change	7.34%	8.89%	4.71%
Gross Profit Margin	96.92%	97.81%	97.43%
Selling, General & Admin	$34.97M	$38.97M	$32.67M
YoY Change	-10.26%	55.26%	23.43%
% of Gross Profit	74.51%	89.12%	84.74%
Research & Development	$30.79M	$37.93M	$33.44M
YoY Change	-18.83%	10.08%	35.75%
% of Gross Profit	65.6%	86.75%	86.75%
Depreciation & Amortization	$5.850M	$4.840M	$4.901M
YoY Change	20.87%	4.31%	12.72%
% of Gross Profit	12.46%	11.07%	12.71%
Operating Expenses	$65.76M	$81.24M	$77.80M
YoY Change	-19.05%	29.16%	38.08%
Operating Profit	-$23.11M	-$36.53M	-$38.23M
YoY Change	-36.73%	69.43%	113.42%
Interest Expense	-$4.634M	-$4.817M	-$4.865M
YoY Change	-3.8%	355.72%	321.21%
% of Operating Profit
Other Income/Expense, Net	-$2.892M	-$2.103M	-$2.348M
YoY Change	37.52%	249.34%	890.72%
Pretax Income	-$26.00M	-$38.63M	-$40.58M
YoY Change	-32.69%	74.32%	123.57%
Income Tax	$65.00K	$69.00K	$401.0K
% Of Pretax Income
Net Earnings	-$26.07M	-$38.70M	-$40.98M
YoY Change	-32.64%	73.32%	122.97%
Net Earnings / Revenue	-53.83%	-86.57%	-103.56%
Basic Earnings Per Share	-$0.58		-$0.99
Diluted Earnings Per Share	-$0.58	-$922.3K	-$0.99
COMMON SHARES
Basic Shares Outstanding	44.76M shares	41.44M shares	41.41M shares
Diluted Shares Outstanding	44.76M shares		41.41M shares

Balance Sheet

Concept	2020 Q2	2019 Q2	2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$370.3M	$298.4M	$270.7M
YoY Change	24.1%	16.7%	2.52%
Cash & Equivalents	$237.2M	$75.66M	$69.84M
Short-Term Investments	$133.1M	$222.7M	$200.8M
Other Short-Term Assets	$7.700M	$10.60M	$9.600M
YoY Change	-27.36%	92.73%	108.7%
Inventory	$6.286M	$5.050M	$5.571M
Prepaid Expenses
Receivables	$14.10M	$15.50M	$12.71M
Other Receivables	$20.10M	$0.00	$0.00
Total Short-Term Assets	$505.6M	$457.0M	$475.5M
YoY Change	10.62%	63.85%	65.8%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.930M	$3.015M	$2.995M
YoY Change	-2.82%	-12.74%	-1.55%
Goodwill	$936.0K	$936.0K	$936.0K
YoY Change	0.0%	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments		$15.00M	$15.00M
YoY Change		0.0%	0.0%
Other Assets	$13.90M	$12.70M	$13.47M
YoY Change	9.39%	137.38%	108.63%
Total Long-Term Assets	$173.1M	$190.6M	$192.2M
YoY Change	-9.15%	-10.21%	-10.2%
TOTAL ASSETS
Total Short-Term Assets	$505.6M	$457.0M	$475.5M
Total Long-Term Assets	$173.1M	$190.6M	$192.2M
Total Assets	$678.7M	$647.6M	$667.7M
YoY Change	4.81%	31.85%	33.32%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$10.20M	$12.52M	$7.627M
YoY Change	-18.54%	59.54%	-19.06%
Accrued Expenses	$44.38M	$50.56M	$46.62M
YoY Change	-12.22%	43.34%	47.32%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due		$0.00	$22.50M
YoY Change		-100.0%
Total Short-Term Liabilities	$69.93M	$90.59M	$104.1M
YoY Change	-22.8%	-12.47%	84.12%
LONG-TERM LIABILITIES
Long-Term Debt	$210.0M	$199.9M	$197.5M
YoY Change	5.05%		336.95%
Other Long-Term Liabilities	$19.51M	$22.10M	$23.41M
YoY Change	-11.74%	352.91%	407.08%
Total Long-Term Liabilities	$19.51M	$22.10M	$23.41M
YoY Change	-11.74%	352.91%	407.08%
TOTAL LIABILITIES
Total Short-Term Liabilities	$69.93M	$90.59M	$104.1M
Total Long-Term Liabilities	$19.51M	$22.10M	$23.41M
Total Liabilities	$360.0M	$370.5M	$382.0M
YoY Change	-2.82%	82.37%	89.73%
SHAREHOLDERS EQUITY
Retained Earnings	-$441.7M	-$349.7M	-$311.0M
YoY Change	26.31%	68.09%	67.46%
Common Stock	$759.0M	$626.0M	$596.6M
YoY Change	21.24%	25.91%	22.59%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$318.6M	$277.1M	$285.7M
YoY Change
Total Liabilities & Shareholders Equity	$678.7M	$647.6M	$667.7M
YoY Change	4.81%	31.85%	33.32%

Cashflow Statement

Concept	2020 Q2	2019 Q2	2019 Q1
OPERATING ACTIVITIES
Net Income	-$26.07M	-$38.70M	-$40.98M
YoY Change	-32.64%	73.32%	122.97%
Depreciation, Depletion And Amortization	$5.850M	$4.840M	$4.901M
YoY Change	20.87%	4.31%	12.72%
Cash From Operating Activities	-$6.450M	-$19.11M	-$20.49M
YoY Change	-66.25%	592.39%	39.08%
INVESTING ACTIVITIES
Capital Expenditures	-$4.440M	-$3.390M	$19.00K
YoY Change	30.97%	-9.12%	-51.28%
Acquisitions
YoY Change
Other Investing Activities	$72.23M	$28.62M	-$7.430M
YoY Change	152.38%	-9.57%	-41.03%
Cash From Investing Activities	$67.80M	$25.23M	-$11.41M
YoY Change	168.73%	-9.6%	-45.27%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$108.7M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	108.8M	-320.0K	-$1.110M
YoY Change	-34096.87%	-110.39%	-58.92%
NET CHANGE
Cash From Operating Activities	-6.450M	-19.11M	-$20.49M
Cash From Investing Activities	67.80M	25.23M	-$11.41M
Cash From Financing Activities	108.8M	-320.0K	-$1.110M
Net Change In Cash	170.1M	5.800M	-$33.04M
YoY Change	2833.45%	-79.45%	-13.69%
FREE CASH FLOW
Cash From Operating Activities	-$6.450M	-$19.11M	-$20.49M
Capital Expenditures	-$4.440M	-$3.390M	$19.00K
Free Cash Flow	-$2.010M	-$15.72M	-$20.51M
YoY Change	-87.21%	-1720.62%	38.84%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001438533
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Amendment Flag AmendmentFlag	false
	dei	Entity Address Address Line1 EntityAddressAddressLine1	3721 Valley Centre Drive
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92130
	dei	City Area Code CityAreaCode	888
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 200
	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
CY2020Q2	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	218596000	USD
CY2019Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	335206000	USD
CY2020Q2	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	USD
CY2019Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	USD
CY2020Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2020Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2020Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	50902874	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	43088921	shares
CY2020Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	50902874	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	43088921	shares
	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	us-gaap:AccountingStandardsUpdate201613Member
CY2020Q2	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	us-gaap:OtherAssetsNoncurrent
CY2020Q2	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	us-gaap:OtherLiabilitiesCurrent
CY2020Q2	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	us-gaap:OtherLiabilitiesNoncurrent
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2020-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-36257
	dei	Entity Registrant Name EntityRegistrantName	RETROPHIN, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	27-4842691
	dei	Local Phone Number LocalPhoneNumber	969-7879
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
	dei	Trading Symbol TradingSymbol	RTRX
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2020Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	50905923	shares
CY2020Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	237170000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	62436000	USD
CY2020Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	220206000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	336088000	USD
CY2020Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	14077000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	18048000	USD
CY2020Q2	us-gaap	Inventory Net InventoryNet	6286000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	6082000	USD
CY2020Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7714000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5015000	USD
CY2020Q2	us-gaap	Income Tax Receivable IncomeTaxReceivable	20109000	USD
CY2019Q4	us-gaap	Income Tax Receivable IncomeTaxReceivable	1395000	USD
CY2020Q2	us-gaap	Assets Current AssetsCurrent	505562000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	429064000	USD
CY2020Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2930000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2891000	USD
CY2020Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	13895000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	14709000	USD
CY2020Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	155371000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	157200000	USD
CY2020Q2	us-gaap	Goodwill Goodwill	936000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	936000	USD
CY2020Q2	us-gaap	Assets Assets	678694000	USD
CY2019Q4	us-gaap	Assets Assets	604800000	USD
CY2020Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	10198000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	26614000	USD
CY2020Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	44379000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	51745000	USD
CY2020Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	7356000	USD
CY2019Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	8590000	USD
CY2020Q2	rtrx	Acquisition Related Contingent Consideration AcquisitionRelatedContingentConsideration	8000000	USD
CY2019Q4	rtrx	Acquisition Related Contingent Consideration AcquisitionRelatedContingentConsideration	8500000	USD
CY2020Q2	us-gaap	Liabilities Current LiabilitiesCurrent	69933000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	95449000	USD
CY2020Q2	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	210009000	USD
CY2019Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	204861000	USD
CY2020Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	19507000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	20894000	USD
CY2020Q2	rtrx	Acquisition Related Contingent Consideration Noncurrent AcquisitionRelatedContingentConsiderationNoncurrent	60600000	USD
CY2019Q4	rtrx	Acquisition Related Contingent Consideration Noncurrent AcquisitionRelatedContingentConsiderationNoncurrent	62400000	USD
CY2020Q2	us-gaap	Liabilities Liabilities	360049000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	383604000	USD
CY2020Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q2	us-gaap	Common Stock Value CommonStockValue	5000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	4000	USD
CY2020Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	758945000	USD
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	636910000	USD
CY2020Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-441704000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-416444000	USD
CY2020Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1399000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	726000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	318645000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	221196000	USD
CY2020Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	678694000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	604800000	USD
CY2020Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	48430000	USD
CY2019Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	44707000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	96199000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	84277000	USD
CY2020Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1494000	USD
CY2019Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	979000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2864000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1996000	USD
CY2020Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	30790000	USD
CY2019Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	37934000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	61038000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	71377000	USD
CY2020Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	34971000	USD
CY2019Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	38970000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	68110000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	71639000	USD
CY2020Q2	rtrx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	4286000	USD
CY2019Q2	rtrx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	3353000	USD
	rtrx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	2363000	USD
	rtrx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	6522000	USD
CY2020Q2	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2019Q2	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	25500000	USD
CY2020Q2	rtrx	Write Off Of Contingent Consideration WriteOffOfContingentConsideration	0	USD
CY2019Q2	rtrx	Write Off Of Contingent Consideration WriteOffOfContingentConsideration	0	USD
	rtrx	Write Off Of Contingent Consideration WriteOffOfContingentConsideration	0	USD
	rtrx	Write Off Of Contingent Consideration WriteOffOfContingentConsideration	18000000	USD
CY2020Q2	us-gaap	Costs And Expenses CostsAndExpenses	71541000	USD
CY2019Q2	us-gaap	Costs And Expenses CostsAndExpenses	81236000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	134375000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	159034000	USD
CY2020Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-23111000	USD
CY2019Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-36529000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-38176000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-74757000	USD
CY2020Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	426000	USD
CY2019Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	125000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	235000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-177000	USD
CY2020Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	1316000	USD
CY2019Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	2589000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	3291000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	5408000	USD
CY2020Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-4634000	USD
CY2019Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-4817000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-9521000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-9682000	USD
CY2020Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2892000	USD
CY2019Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2103000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5995000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4451000	USD
CY2020Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-26003000	USD
CY2019Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-38632000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-44171000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-79208000	USD
CY2020Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	65000	USD
CY2019Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	69000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-18911000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	470000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-26068000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-38701000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-25260000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-79678000	USD
CY2020Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.58
CY2019Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.92
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.57
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.91
CY2020Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	44763843	shares
CY2019Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	41957860	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	43943370	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	41685599	shares
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-26068000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-38701000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-25260000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-79678000	USD
CY2020Q2	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-247000	USD
CY2019Q2	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-91000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-56000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	27000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	3146000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	815000	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	729000	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	2284000	USD
CY2020Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-23169000	USD
CY2019Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-37977000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-24587000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-77367000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-25260000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-79678000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	11507000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	9742000	USD
	rtrx	Noncash Interest Expense NoncashInterestExpense	893000	USD
	rtrx	Noncash Interest Expense NoncashInterestExpense	798000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-337000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	580000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	5147000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	4933000	USD
	rtrx	Provision Benefit For Inventory ProvisionBenefitForInventory	662000	USD
	rtrx	Provision Benefit For Inventory ProvisionBenefitForInventory	-358000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	11474000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	11947000	USD
	rtrx	Employee Stock Purchase Plan Expense EmployeeStockPurchasePlanExpense	390000	USD
	rtrx	Employee Stock Purchase Plan Expense EmployeeStockPurchasePlanExpense	345000	USD
	rtrx	Net Changein Fair Valueof Contingent Consideration NetChangeinFairValueofContingentConsideration	2363000	USD
	rtrx	Net Changein Fair Valueof Contingent Consideration NetChangeinFairValueofContingentConsideration	-11478000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-8674000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-2767000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	25500000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	222000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-14000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-496000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-60000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-3979000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2396000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	875000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-918000	USD
	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	18714000	USD
	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	0	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	2508000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	10101000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-16407000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	6305000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-196000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	7195000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-35608000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-39601000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	518000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	21000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	8532000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	7347000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	153146000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	115998000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	36743000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	94812000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	107353000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	13818000	USD
	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	6101000	USD
	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	1722000	USD
	rtrx	Payment Of Guaranteed Minimum Royalty PaymentOfGuaranteedMinimumRoyalty	1050000	USD
	rtrx	Payment Of Guaranteed Minimum Royalty PaymentOfGuaranteedMinimumRoyalty	1034000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	431000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	317000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	108644000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1098000	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1005000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	103022000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1434000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-33000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	174734000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-27216000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	62436000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	102873000	USD
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	237170000	USD
CY2019Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	75657000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	225748000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	285712000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	5760000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	5577000	USD
CY2020Q2	us-gaap	Stock Granted During Period Value Sharebased Compensation Gross StockGrantedDuringPeriodValueSharebasedCompensationGross	371000	USD
CY2019Q2	us-gaap	Stock Granted During Period Value Sharebased Compensation Gross StockGrantedDuringPeriodValueSharebasedCompensationGross	12000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	108644000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	3146000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	815000	USD
CY2020Q2	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	-247000	USD
CY2019Q2	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	-91000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	22590000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1291000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1176000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-26068000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-38701000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	318645000	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	277089000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	221196000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	318253000	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	11474000	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	11947000	USD
	us-gaap	Stock Granted During Period Value Sharebased Compensation Gross StockGrantedDuringPeriodValueSharebasedCompensationGross	431000	USD
	us-gaap	Stock Granted During Period Value Sharebased Compensation Gross StockGrantedDuringPeriodValueSharebasedCompensationGross	317000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	108644000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	729000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	2284000	USD
	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	-56000	USD
	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	26000	USD
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	22590000	USD
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1487000	USD
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1350000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-25260000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-79678000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	318645000	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	277089000	USD
	us-gaap	Nature Of Operations NatureOfOperations	DESCRIPTION OF BUSINESS<div style="margin-top:12pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#006ebf;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Organization and Description of Business</span></div><div style="text-align:justify;margin-top:3pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">Retrophin, Inc. (“we”, “our”, “us”, “Retrophin” and the “Company”) refers to Retrophin, Inc., a Delaware corporation, as well as our direct and indirect subsidiaries. Retrophin is a fully integrated biopharmaceutical company headquartered in San Diego, California, focused on identifying, developing and delivering life-changing therapies to people living with rare diseases. We regularly evaluate and, where appropriate, act on opportunities to expand our product pipeline through licenses and acquisitions of products in areas that will serve patients with serious or rare diseases and that we believe offer attractive growth characteristics.</span></div><div style="text-align:justify;margin-top:3pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">On January 30, 2020, the World Health Organization (“WHO”) declared that the recent novel coronavirus (COVID-19) outbreak was a global health emergency, which prompted national governments to begin putting actions in place to slow the spread of COVID-19. In March 2020, the WHO classified the COVID-19 outbreak as a pandemic. The outbreak of COVID-19 has resulted in travel restrictions, quarantines, “stay-at-home” and “shelter-in-place” orders and extended shutdown of certain businesses around the world. While the impact of the COVID-19 pandemic did not have a material adverse effect on our financial position or results of operations for the three and six months ended June 30, 2020, these governmental actions and the widespread economic disruption arising from the pandemic have the potential to materially impact our business and influence our business decisions. The extent and duration of the pandemic is unknown, and the future effects on our business are uncertain and difficult to predict. The Company is continuing to monitor the events and circumstances surrounding the COVID-19 pandemic, which may require adjustments to the Company’s estimates and assumptions in the future.</span></div><div style="margin-top:9pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#666666;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Clinical Programs:</span></div><div style="margin-top:3pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">Sparsentan</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;">,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%;"> also known as RE-021, is an investigational product candidate with a dual mechanism of action, selective endothelin receptor antagonist (“ERA”), with in vitro selectivity toward endothelin receptor type A, and a potent angiotensin receptor blocker (“ARB”). Sparsentan is currently being evaluated in two pivotal Phase 3 clinical studies in the following indications:</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:9pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#4c4c4c;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:700;line-height:120%;padding-left:15.42pt;">Focal segmental glomerulosclerosis ("FSGS")</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%;"> is a rare kidney disease characterized by proteinuria where the glomeruli become progressively scarred. FSGS is a leading cause of end-stage renal disease.</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:9pt;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#4c4c4c;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:700;line-height:120%;padding-left:15.42pt;">Immunoglobulin A nephropathy ("IgAN")</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%;"> is an immune-complex-mediated glomerulonephritis characterized by hematuria, proteinuria, and variable rates of progressive renal failure. IgAN is the most common primary glomerular disease.</span></div><div style="margin-top:3pt;margin-bottom:6pt;"><span><br/></span></div><div style="margin-top:3pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">Chenodal® has been recognized as the standard of care for cerebrotendinous xanthomatosis (“CTX”) patients for more than three decades but is not currently labeled for this indication. In January 2020, we randomized the first patients in a Phase 3 clinical trial to evaluate the effects of Chenodal in adult and pediatric patients with CTX. The pivotal study, known as the RESTORE study, is intended to support a new drug application (“NDA”) submission for marketing authorization of Chenodal for CTX in the United States.</span></div><div style="margin-top:9pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#666666;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cooperative Research and Development Agreements ("CRADAs"):</span></div><div style="margin-top:3pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">The Company is a participant in two CRADAs, which form a multi-stakeholder approach to pool resources with leading experts, and incorporates the patient perspective early in the identification and development process. Retrophin has partnered with the National Institutes of Health’s National Center for Advancing Translational Sciences ("NCATS") and leading patient advocacy organizations, NGLY1.org and Alagille Syndrome Alliance ("ALGSA"), aimed at the identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome, respectively. There are no treatment options currently approved for these diseases.</span></div><div style="text-align:justify;margin-top:9pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#666666;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Approved products:</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:3pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:15.42pt;">Chenodal (chenodiol tablets) is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. Chenodal has been the standard of care for CTX patients for more than three decades.</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:3pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">•</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:15.42pt;">Cholbam® (cholic acid capsules) is approved in the United States for the treatment of bile acid synthesis disorders due to single enzyme defects and is further indicated for adjunctive treatment of patients with peroxisomal disorders.</span></div>•Thiola® and Thiola EC® (tiopronin tablets) are approved in the United States for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria.
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	84277000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	96199000	USD
CY2020Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	14100000	USD
CY2020Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	220200000	USD
CY2020Q2	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	USD
CY2020Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	48430000	USD
CY2019Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	44707000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	153300000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	36700000	USD
CY2020Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	220206000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	336088000	USD
CY2020Q2	rtrx	Debt Securities Availableforsale Amortized Cost Basis Current DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent	132352000	USD
CY2020Q2	rtrx	Debt Securities Available For Sale Unrealized Gain Current DebtSecuritiesAvailableForSaleUnrealizedGainCurrent	770000	USD
CY2020Q2	rtrx	Debt Securities Available For Sale Unrealized Loss Current DebtSecuritiesAvailableForSaleUnrealizedLossCurrent	0	USD
CY2020Q2	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	133122000	USD
CY2020Q2	rtrx	Debt Securities Availableforsale Amortized Cost Basis Noncurrent DebtSecuritiesAvailableforsaleAmortizedCostBasisNoncurrent	86244000	USD
CY2020Q2	rtrx	Debt Securities Available For Sale Unrealized Gain Noncurrent DebtSecuritiesAvailableForSaleUnrealizedGainNoncurrent	849000	USD
CY2020Q2	rtrx	Debt Securities Available For Sale Unrealized Loss Noncurrent DebtSecuritiesAvailableForSaleUnrealizedLossNoncurrent	9000	USD
CY2020Q2	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	87084000	USD
CY2020Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	218596000	USD
CY2020Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1619000	USD
CY2020Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	9000	USD
CY2020Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	220206000	USD
CY2019Q4	rtrx	Debt Securities Availableforsale Amortized Cost Basis Current DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent	208906000	USD
CY2019Q4	rtrx	Debt Securities Available For Sale Unrealized Gain Current DebtSecuritiesAvailableForSaleUnrealizedGainCurrent	598000	USD
CY2019Q4	rtrx	Debt Securities Available For Sale Unrealized Loss Current DebtSecuritiesAvailableForSaleUnrealizedLossCurrent	10000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	209494000	USD
CY2019Q4	rtrx	Debt Securities Availableforsale Amortized Cost Basis Noncurrent DebtSecuritiesAvailableforsaleAmortizedCostBasisNoncurrent	126300000	USD
CY2019Q4	rtrx	Debt Securities Available For Sale Unrealized Gain Noncurrent DebtSecuritiesAvailableForSaleUnrealizedGainNoncurrent	351000	USD
CY2019Q4	rtrx	Debt Securities Available For Sale Unrealized Loss Noncurrent DebtSecuritiesAvailableForSaleUnrealizedLossNoncurrent	57000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	126594000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	335206000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	949000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	67000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	336088000	USD
CY2020Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	5015000	USD
CY2020Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	9000	USD
CY2020Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	0	USD
CY2020Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	0	USD
CY2020Q2	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	5015000	USD
CY2020Q2	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	9000	USD
CY2019Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	79151000	USD
CY2019Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	65000	USD
CY2019Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	7509000	USD
CY2019Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	2000	USD
CY2019Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	86660000	USD
CY2019Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	67000	USD
CY2020Q2	us-gaap	Cost Method Investments CostMethodInvestments	15000000.0	USD
CY2019Q3	us-gaap	Impairment Of Retained Interest ImpairmentOfRetainedInterest	15000000.0	USD
CY2020Q1	rtrx	Lessee Operating Lease Remeasurement Adjustment To Rou Asset And Lease Liability LesseeOperatingLeaseRemeasurementAdjustmentToROUAssetAndLeaseLiability	7000000.0	USD
CY2020Q2	rtrx	Lessee Operating Lease Remeasurement Adjustment To Rou Asset And Lease Liability LesseeOperatingLeaseRemeasurementAdjustmentToROUAssetAndLeaseLiability	500000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1207000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	960000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1543000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1590000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1637000	USD
CY2020Q2	rtrx	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	6435000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	13372000	USD
CY2020Q2	us-gaap	Lease Incentive Receivable LeaseIncentiveReceivable	1983000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	3121000	USD
CY2020Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	8268000	USD
CY2020Q2	rtrx	Operating Lease Incentive Tenant Improvements OperatingLeaseIncentiveTenantImprovements	404000	USD
CY2020Q2	rtrx	Straight Line Lease Expense In Excess Of Cash Payments StraightLineLeaseExpenseInExcessOfCashPayments	952000	USD
CY2020Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6912000	USD
CY2020Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6900000	USD
CY2020Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1379000	USD
CY2020Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	6889000	USD
CY2020Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	8268000	USD
CY2020Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	200000	USD
CY2019Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	0	USD
	us-gaap	Operating Lease Expense OperatingLeaseExpense	600000	USD
	us-gaap	Operating Lease Expense OperatingLeaseExpense	1300000	USD
	us-gaap	Number Of Businesses Acquired NumberOfBusinessesAcquired	2	business
CY2020Q2	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	225900000	USD
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	237170000	USD
CY2020Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	220206000	USD
CY2020Q2	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	457376000	USD
CY2020Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	68600000	USD
CY2020Q2	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	68600000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	62436000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	336088000	USD
CY2019Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	398524000	USD
CY2019Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	70900000	USD
CY2019Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	70900000	USD
CY2020Q2	rtrx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	4300000	USD
	rtrx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	2400000	USD
CY2019Q2	rtrx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	3400000	USD
CY2020Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	155400000	USD
CY2020Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	254443000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	245802000	USD
CY2020Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	99072000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	88602000	USD
CY2020Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	155371000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	157200000	USD
CY2020Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5285000	USD
CY2019Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	4856000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	10459000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	9587000	USD
CY2020Q2	us-gaap	Debt Instrument Repurchase Amount DebtInstrumentRepurchaseAmount	23400000	USD
CY2019Q2	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	1300000	shares
CY2020Q2	rtrx	Government Rebates Payable GovernmentRebatesPayable	7817000	USD
CY2019Q4	rtrx	Government Rebates Payable GovernmentRebatesPayable	6584000	USD
CY2020Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	10011000	USD
CY2019Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	14045000	USD
CY2020Q2	rtrx	Accrued Royaltyand Contingent Consideration AccruedRoyaltyandContingentConsideration	7432000	USD
CY2019Q4	rtrx	Accrued Royaltyand Contingent Consideration AccruedRoyaltyandContingentConsideration	7272000	USD
CY2020Q2	rtrx	Accrued Liabilities Researchand Development Current AccruedLiabilitiesResearchandDevelopmentCurrent	8369000	USD
CY2019Q4	rtrx	Accrued Liabilities Researchand Development Current AccruedLiabilitiesResearchandDevelopmentCurrent	16067000	USD
CY2020Q2	rtrx	Accrued Liabilities Selling Generaland Administrative Current AccruedLiabilitiesSellingGeneralandAdministrativeCurrent	7321000	USD
CY2019Q4	rtrx	Accrued Liabilities Selling Generaland Administrative Current AccruedLiabilitiesSellingGeneralandAdministrativeCurrent	3552000	USD
CY2020Q2	rtrx	Accrued Liabilities Miscellaneous AccruedLiabilitiesMiscellaneous	3429000	USD
CY2019Q4	rtrx	Accrued Liabilities Miscellaneous AccruedLiabilitiesMiscellaneous	4225000	USD
CY2020Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	44379000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	51745000	USD
CY2020Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	44763843	shares
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-26068000	USD
CY2020Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.58
CY2019Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	41957860	shares
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-38701000	USD
CY2019Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.92
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	43943370	shares
	us-gaap	Net Income Loss NetIncomeLoss	-25260000	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.57
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	41685599	shares
	us-gaap	Net Income Loss NetIncomeLoss	-79678000	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.91
CY2020Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	17110450000	shares
CY2019Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16512348000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16878538000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16564478000	shares
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	18000000.0	USD
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	5300000	shares
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	19.20
CY2020Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5954000	USD
CY2019Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5748000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	11864000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12268000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-18900000	USD
CY2020Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	3037000	USD
CY2019Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2713000	USD
CY2020Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	3249000	USD
CY2019Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	3369000	USD
CY2020Q2	us-gaap	Inventory Net InventoryNet	6286000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	6082000	USD
CY2020Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	3600000	USD
CY2019Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	3100000	USD
CY2020Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	14100000	USD
CY2016Q2	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	500000	USD
CY2016Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	25000000.0	USD
CY2016	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-2300000	USD
CY2017	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-5700000	USD
CY2018	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	1000000.0	USD
CY2019Q1	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	25500000	USD
CY2019Q1	rtrx	Write Off Of Contingent Consideration WriteOffOfContingentConsideration	18000000.0	USD
CY2019Q1	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	-7500000	USD
CY2020Q2	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	7500000	shares
CY2020Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	15.50
CY2020Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	108600000	USD
CY2020Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	100000000.0	USD

Files In Submission

Name	View Source	Status
0001438533-20-000022-index-headers.html	Edgar Link	pending
0001438533-20-000022-index.html	Edgar Link	pending
0001438533-20-000022.txt	Edgar Link	pending
0001438533-20-000022-xbrl.zip	Edgar Link	pending
ex03312020322.htm	Edgar Link	pending
ex06302020311.htm	Edgar Link	pending
ex06302020312.htm	Edgar Link	pending
ex06302020321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
rtrx-20200630.htm	Edgar Link	pending
rtrx-20200630.xsd	Edgar Link	pending
rtrx-20200630_cal.xml	Edgar Link	unprocessable
rtrx-20200630_def.xml	Edgar Link	unprocessable
rtrx-20200630_g1.jpg	Edgar Link	pending
rtrx-20200630_htm.xml	Edgar Link	completed
rtrx-20200630_lab.xml	Edgar Link	unprocessable
rtrx-20200630_pre.xml	Edgar Link	unprocessable
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TVTX
Travere Therapeutics Inc Stock $tvtx

2020 Q2 Form 10-Q Financial Statement

#000143853320000022 Filed on July 31, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TVTX Travere Therapeutics Inc Stock $tvtx

2020 Q2 Form 10-Q Financial Statement

#000143853320000022 Filed on July 31, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TVTX
Travere Therapeutics Inc Stock $tvtx